AP23848

AP23848 is an ATP-dependent kinase inhibitor that effectively and selectively targets the Kit activation loop mutation both in vitro and in vivo, showing anti-tumor activity. AP23848 can inhibit the phosphorylation of the activated Kit mutation and tumor growth in mice, making it suitable for targeting diseases with the D816V mutation, such as systemic mastocytosis (SM) and acute myeloid leukemia (AML) research[1].

Product Specifications

CAS Number

[834894-21-2]

UNSPSC

12352005

Hazard Statement

H302-H315-H319-H335

Target

C-Kit

Related Pathways

Protein Tyrosine Kinase/RTK

Field of Research

Cancer

Smiles

OC1=CC=CC(CCN2C3=NC(C4CCCC4)=NC(NC5=CC=C(P(CCC)(CCC)=O)C=C5)=C3N=C2)=C1

Molecular Formula

C30H38N5O2P

Molecular Weight

531.63

Precautions

P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501

References & Citations

[1]Amie S Corbin, et al. In vitro and in vivo activity of ATP-based kinase inhibitors AP23464 and AP23848 against activation-loop mutants of Kit. Blood. 2005 Jul 1;106 (1) :227-34.